Exploring Menopause, aging and Physiological Outcomes in Women with Intellectual And/or Neurodevelopmental Disabilities  

Summary

This study looks at how lifestyle choices like exercise and diet, along with certain genes called HERVs, affect aging and telomere length in individuals with intellectual and developmental disabilities. It will explore whether healthy habits can help slow down early aging in this population, who often face more health problems, like early menopause. By examining how these habits impact telomere length and whether HERV expression can show signs of early aging, researchers aim to help healthcare professionals and caregivers create personalized care plans to support healthy aging.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 25 to 100

Accepts healthy participants: Yes

Inclusion criteria:

Individuals who
1) Have or have had a womb
2) Aged 25 years or older
3) Identify as having an Intellectual Disability AND/OR Down Syndrome, OR as Neurotypical

Exclusion criteria:

You are not eligible to participate if you are
1) Unable to provide informed consent and/or assent
2) Unable to provide consent for a blood sample
3) Have a severe illness or hospitalization at the time of recruitment
4) Have HIV, HCV, HBV, or other immunocompromising conditions
5) Currently on antibiotics or immunosuppressive therapy
6) Have other conditions that may affect study outcomes, such as severe illness, narcotic addiction, or pregnancy

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

For more information or to participate, please contact Dr. Laura St. John by email at laura.stjohn@ucalgary.ca or by phone at 403-220-8954.

Principal investigator:

Laura St.John

Clinical trial:

No

REB-ID:

REB25-0050